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Background: Several guidelines have advocated the need for adequate cancer-related pain 
(CRP) management. The pain management index (PMI) has been proposed as an auditable 
measure of the appropriateness for analgesic therapy. 
Objectives: To determine the adequacy of CRP management based on the PMI status and its 
patient-related predictors at the point of referral to a pain clinic (PC). 
Methods: Consecutive patients referred to a PC had standardized initial assessments and status 
documentation on the Brief Pain Inventory (BPI) ratings; pain mechanism, using a neuropathic 
pain diagnostic questionnaire (the Douleur Neuropathique 4 tool); episodic pain; oral morphine 
equivalent daily dose; the Hospital Anxiety Depression Scale and the Emotion Thermometer 
scores; and cancer diagnosis, metastases, treatment, and pain duration. Predictors of “negative 
PMI status” [PMI(−)] were examined in logistic regression models. Variables with p<0.25 in 
an initial bivariable analysis were entered into a multivariable model. 
Results: Of 371 participants, 95 (25.6%) had PMI(−), suggesting undertreatment of CRP. Both 
female sex and higher scores on the BPI’s “interference with general activity” more strongly 
predicted PMI(−). Patients who received either radiotherapy or one or more adjuvant analgesics 
prior to the initial consultation at the PC, those who had neuropathic pain, those who had a 
greater need for emotional help, and those with higher BPI’s “relief ” scores were all less likely 
to be PMI(−).
Conclusion: The potential burden of patient and family distress associated with suboptimal CRP 
management in one in four patients should generate major public health concern and prompt 
appropriate educational and health policy measures to address the deficit.
Keywords: cancer pain, pain management, opioid analgesics, pain measurement
Introduction
Cancer-related pain (CRP) is a burdensome symptom with the potential to negatively 
impact patients’ and their families’ quality of life.1 A recent meta-analysis reported 
pooled prevalence rates of 55% for CRP in patients who were receiving disease 
modifying treatment and 64% in those with advanced metastatic or terminal disease.2 
CRP may be controlled in up to 90% cases with appropriate analgesic therapies.3 
Several authors have highlighted the need for adequate control of CRP and many 
published guidelines advocate a standardized strategic approach to its management.4–9 
The World Health Organization (WHO) pain ladder forms the basis of most CRP 
management guidelines.4 This advocates the use of analgesic medication in a three-
step approach to achieve CRP relief. Step 1 involves the use of non-opioids such as 
paracetamol for mild pain. Step 2 advises the use of a weak opioid for persistent pain 
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or pain increasing to moderate level. Step 3 for moderate 
to severe pain advocates the use of a strong opioid such as 
morphine when moderate pain is persisting or increasing to 
a severe level. 
Although control of CRP is attainable in most patients 
with treatment modalities that are available and relatively 
safe, many cancer patients suffer unnecessarily due to inad-
equate control of CRP.10 This inadequacy is multifactorial; 
it is associated in particular with negative perceptions and 
various barriers that originate from among patients, families, 
informal caregivers, health care providers, institutions, and 
society in general.1
As pharmacological therapy is the mainstay of CRP man-
agement,4 adequacy of pain management can be reflected by 
the appropriateness of the analgesic prescribed.11 Based on 
the assumption that the goal of cancer pain control is to enable 
patients to function at an optimal level, and ultimately in the 
terminal phase to die relatively free of pain, CRP treatment 
is inadequate when substantial pain persists, regardless of 
the reason for this failure, such as insufficient use of pain 
medication and other procedures.12 
The pain management index (PMI) is an auditable mea-
sure of the appropriateness of analgesic therapy.13 It is a 
composite measure reflecting the patient’s pain severity and 
the appropriateness of the strength of the analgesic used in 
relation to the reported pain severity.14
A 1993 study, based on the WHO cancer pain manage-
ment guidelines, found that 42% of outpatients with CRP 
received inadequate analgesic therapy.15 A systematic review 
which included 26 studies, published between 1994 and 
2007, reported that potential undertreatment, based on PMI 
status, varied in prevalence from 8% to 82%.16 In a more 
recent review of 20 studies, from the 2007 to 2013 period, 
there was a decrease in the prevalence of undertreatment but 
it remains significantly high at 31.8%.17 
The epidemiology of CRP and its treatment in Portugal 
are not well documented, but undertreatment is to be expected 
as strong opioids are only prescribed to a small proportion of 
eligible patients.18 A population-based study of chronic pain, 
including 49 patients with cancer pain, reported that opioids 
were used in only 10.13% of those with CRP.19 Given the 
limited published data in the Portuguese context, the aim of 
this study was to determine the adequacy of CRP manage-
ment based on PMI status and identify its patient-related 
predictors at the point of referral to a cancer pain clinic 
(PC). The collection of these data may help to focus future 
educational, research, and health policy development in the 
management of CRP. 
Methods
Setting and design
The present study was conducted from June 1, 2009 to 
April 30, 2010 in the specialist PC of the Portuguese Cancer 
Institute, a national tertiary-level cancer center in Lisbon, 
Portugal. The study was cross-sectional in design, reflecting 
assessments that were conducted at subjects’ first consulta-
tion in the PC.
Study population and eligibility criteria
Consecutive new patient referrals to an outpatient PC were 
approached for consent to participate in both an initial cross-
sectional and a related longitudinal study of CRP characteris-
tics and management. The following eligibility criteria were 
applied: adult patients (>18 years of age) were included if 
they had a cancer diagnosis, provided informed consent to 
participate in the study, and had the cognitive capacity to rate 
their current pain on a numerical rating scale (0 meaning no 
pain, 10 meaning the worst pain imaginable); patients were 
excluded if they had no evidence of active cancer or had non-
CRP. CRP was defined as pain directly related to malignant 
involvement or pain related to anticancer treatment, such as 
chemotherapy, radiotherapy, or surgery. Ethics approval for 
the present study was obtained from the Research Ethics 
Board of the Portuguese Cancer Institute (Lisbon, Portugal). 
Assessment data and tools
Patients underwent standardized assessments and documen-
tation of clinical data. Translated Portuguese versions of 
standard tools previously validated in English and also, in 
most cases, in Portuguese were used. 
Recorded demographic data included sex, education, 
marital status, income per month (euros), and socioeconomic 
status. Regarding education, primary referred to 0–4 years 
of education; secondary referred to 5–12 years; and tertiary 
referred to university or >12 years. For ease of reporting, the 
Portuguese socioeconomic groupings of 1, 2, and 3; 4, 5, and 
6; 7 and 8; and 9 were transformed in a similar descending 
order to groups 1, 2, 3, and 4, respectively.20 
Scores ≥4 on a Portuguese-translated version (unpub-
lished) of the original Short Portable Mental Status Ques-
tionnaire were used to screen for cognitive impairment.21 
Performance status (0–4: 0, fully active and able to carry 
on all predisease performance tasks without restriction; 4, 
indicating that the patient is unable to provide self-care and 
confined to bed or chair) was rated using the Eastern Coop-
erative Oncology Group (ECOG) scale.22 Scores >7 on the 
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Cancer-related pain management and predictors of undertreatment
Depression Scale (HADS) and >4 on the Emotion Thermom-
eter (ET) tool were used to screen for anxiety, depression, 
and emotional distress, respectively.23,24
The recording of cancer characteristics included primary 
cancer diagnosis, metastases, cancer disease modifying treat-
ments ≤30 days before the first PC consultation (cytotoxic 
chemotherapy, radiotherapy, or surgery), and documentation 
of palliative status (in relation to the goals of treatment). 
Pain data included pain mechanisms (nociceptive and/
or neuropathic), episodic pain, analgesic drugs prescribed 
before the first PC consultation, pain duration, and the Brief 
Pain Inventory (BPI) score.25,26 A score of ≥4 of the “Douleur 
Neuropathique 4” (DN4) was used to designate a positive 
DN4 status, meaning that CRP mechanism screened positive 
for a neuropathic component (NeuCP).26,27 Episodic pain, 
defined as a transitory exacerbation of pain that occurs in 
addition to otherwise stable persistent pain,28 was recorded 
and subdivided into episodic incident pain (when a trigger or 
incident activity was identifiable) and episodic breakthrough 
pain (when no trigger was identified). The oral morphine 
equivalent daily dose (MEDD) was calculated according 
to standard recommendations29 and recorded along with the 
number of current adjuvant (pharmacological) analgesic 
treatments (grouped as none and one or more).
PMI
The PMI reflects a level of congruence between a patient’s 
reported pain intensity and the potency of their analgesia at 
the point of initial assessment in the PC. BPI average scores 
in the none (0), mild (1–3), moderate (4–6), and severe 
(7–10) pain intensity categories were graded as 0, 1, 2, and 
3, respectively, as “pain severity ratings” for computing 
the PMI values. The grading of “analgesic drug class” for 
PMI computation was determined by the most potent level 
of analgesic drug prescribed to the patient before their first 
PC consultation and categorized as 0=no analgesic drugs; 
1=nonopioid drugs (eg, paracetamol); 2=weak opioids (eg, 
codeine); and 3=strong opioids (eg, fentanyl). The PMI 
value for each patient was then computed by subtracting 
the patient’s pain severity rating from the grade of analgesic 
drug class. 
The PMI values range from −3 (a patient with severe pain, 
but receiving no analgesic drugs) to +3 (a patient reporting no 
pain and having been prescribed morphine or an equivalent 
strong opioid). Negative PMI values [PMI(−)] are considered 
to indicate pain undertreatment (inadequate CRP manage-
ment), and positive PMI values of 0–3 [PMI(+)] are consid-
ered a conservative indicator of acceptable treatment.13,14 
Data analyses
Data were analyzed using the software Stata® (version 
14; StataCorp LP, College Station, TX, USA). Means are 
expressed with standard deviations (SDs). Continuous and 
categorical variables were compared using Student’s t-tests, 
and chi-square tests or Fisher’s exact tests, respectively. The 
initial MEDD was highly skewed and underwent logarithmic 
transformation for further analysis.
Predictors of PMI(−) were examined in logistic regression 
models, generating odds ratios (ORs) and 95% confidence 
intervals (CIs). The specification of independent variables 
for multivariable logistic regression analyses was based on a 
combination of clinical plausibility, the need to avoid multi-
collinearity, review of the literature, and the results of initial 
bivariable analyses comparing the groups with negative and 
positive PMI status. Variables with p<0.25 in the bivariable 
analyses were considered for entry in multivariable models. 
A backward elimination approach was used to derive a final 
model. The Hosmer–Lemeshow test and the area under 
receiver operating characteristic curve (AU-ROC) were used 
to assess each model’s goodness of fit and discrimination 
threshold. Statistical significance was set at p<0.05. 
Results
The derivation of the study sample and a summary of patients’ 
PMI status is presented in Figure 1. Of 459 individuals who 
were screened for the study, 88 were excluded because of 
non-CRP, nonactive cancer, or failure to consent, resulting 
in a final study sample of 371 patients. Of these, 95 (25.6%) 
had PMI(−), suggesting undertreatment of their cancer pain. 
Most of the PMI(−) values were in the −1 category (n=87). 
The derivation and summary of both pain severity grades 
and analgesic drug class grades are presented in Table 1. 
None of the study samples had a BPI average rating of zero. 
Although 77 patients (20.8%) rated their pain as severe, only 
nine (11.7%) of these were prescribed a strong opioid. 
The demographic, cognitive and functional, and clinical 
and psychological variables, as well as their associations with 
the PMI status are shown in Table 2. The mean age of the 
entire study sample was 62.1±14.3 years and 199 (54%) were 
female. Most of the patients had completed only primary edu-
cation (69.8%); most were married (64.1%); approximately 
half of the sample had a monthly income of ≤485 euros; 46 
(12.4%) had a mild cognitive deficit; and 62 (16.7%) were 
rated in the ECOG 3–4 categories. An addictive history screen 
was positive in 86 (23.2%) patients. The HADS screen-
ing scores were positive for depression and anxiety in 280 
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the ET tool for “distress” and “need for help” was positive in 
170 (45.8%) and 167 (45.0%) cases, respectively. The median 
(Q1–Q3) MEDD values in mg for males and females were 
30 (20–60) and 30 (15–60), respectively. The logarithmically 
transformed MEDD values (mean±SD) for males and females 
were 3.39±1.25 and 3.19±1.42 (p=0.053). More detailed 
demographic findings have been described in a previous 
publication.20 Female sex and not needing help (to manage 
emotional problems) had statistically significant associations 
with PMI(−) status. 
The associations of both cancer and pain characteristics 
with PMI status are shown in Table 3. Only 10 (2.7%) patients 
had a lung cancer diagnosis; 263 (71%) had metastatic dis-
ease; and 176 (47.4%) had their treatment goal as palliative. 
In the month prior to their first PC consultation, 167 (45.0%), 
112 (30.2%), and 176 (47.4%) underwent chemotherapy, 
surgery, and radiotherapy, respectively. Screening for NeuCP 
was positive in 161 (43.4%) patients. For analgesia, no opioid 
was prescribed for 42 (11.3%) patients; 210 (56.6%) were 
prescribed one or more adjuvant medications. Pain dura-
tion was over 3 months in 179 (48.2%) patients. Absence 
of head and neck metastatic disease, no exposure to recent 
radiotherapy, and no prescription of opioids at PC referral all 
had a statistically significant association with PMI(−) status. 
Continuous variables (age, the BPI main items, and the 
DN4 scores) and their associations with the PMI status are 
shown in Table 4. A statistically significant association with 
PMI(−) status was noted for higher pain intensity ratings, 
greater interference of pain with general activity, and reported 
lesser pain relief. 
Figure 1 Derivation of study sample and PMI status.
Abbreviation: PMI, pain management index.
Screened for study eligibility: n=459
Included in study sample: n=371
PMI positive value
n=276 (74.4%)
PMI = 0 (n=186)
PMI = 1 (n=82)
PMI negative value
n=95 (25.6%)
PMI = –3 (n=2)
PMI = –2 (n=6)
PMI = –1 (n=87) PMI = 2 (n=8)
Excluded: n=88 (in total)
Noncancer pain (n=69); nonactive cancer
(n=16), and refused consent (n=3)
Table 1 Derivation and summary of PMI grades for pain severity and analgesic drug classes
Pain severity Analgesic drug class prescribed
PMI grade
Categories* PMI grade 0 1 2 3 Total (%)
None (0) 0 0 0 0 0 0
Mild (1–3) 1 18 13 42 8 81 (21.8)
Moderate (4–6) 2 6 3 164 40 213 (57.4)
Severe (7–10) 3 2 0 66 9 77 (20.8)
Total (%) 26 (7.0) 16 (4.3) 272 (73.3) 57 (15.4) 371 (100)
Note: *Descriptive categories (mild, moderate, and severe) are based on patients’ Brief Pain Inventory average pain intensity rating (0–10).
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Cancer-related pain management and predictors of undertreatment
The logistic regression analyses are summarized in 
Table 5. The final multivariable model contained seven 
statistically significant independent predictors of PMI(−). 
In the final model, female sex was arguably an independent 
predictor (OR=1.7; 95% CI 0.99–2.92, p=0.05) of PMI(−). 
Similarly, higher BPI scores for “interference with general 
activity” predicted PMI(−) status (OR=1.14; 95% CI 1.02–
1.27, p=0.02). Negative predictors of PMI(−) included recent 
radiotherapy treatment, adjuvant analgesic use, positive 
NeuCP screening, a reported higher need for emotional help, 
and higher BPI “pain relief ” scores. The Hosmer–Lemeshow 
goodness-of-fit test for the final model had a chi-square test 
value=6.33 (p=0.61) and the AU-ROC was 0.782.
Discussion
Adequacy of CRP management
In this study, patients’ PMI status suggests that CRP manage-
ment was inadequate in 25.6% of individuals: about one in 
four patients were likely undertreated at initial consultation 
in our outpatient cancer PC. This finding was corroborated 
by an almost 20% difference in mean percentage pain relief 
between those with the PMI(−) and the PMI(+) status. Over-
all, the study’s findings are largely consistent with literature 
data in indicating that CRP is still inadequately managed. 
However, it is important to acknowledge contextual and 
methodological differences when comparing this study to 
previously published data. 
Table 2 Demographic, cognitive and functional, and clinical and psychological characteristic variables and their associations with PMI 
status (n=371)
Characteristics PMI positive PMI negative p-value
n % n %
Demographic
Sex Male 136 49.3 36 37.9 0.05
Female 140 50.7 59 62.1
Education Primary 194 70.3 65 68.4 0.78
Secondary 67 24.3 23 24.2
Tertiary 15 5.4 7 7.4
Marital status Single 34 12.3 9 9.5 0.71
Married 173 62.7 65 68.4
Divorced 31 11.2 8 8.4
Widow 38 13.8 13 13.7
Income per month ≤485 euros 127 46.0 49 51.6 0.35
>485 euros 149 54.0 46 48.4
Socioeconomic statusa Group 1 43 15.6 10 10.5 0.56
Group 2 104 37.7 42 44.2
Group 3 62 22.4 21 22.1
Group 4 67 24.3 22 23.2
Cognitive and functional
Cognitive function Normal 244 88.4 81 85.3 0.42
Mild deficit 32 11.6 14 14.7
ECOG 0 88 31.9 32 33.7 0.83
1 96 34.8 32 33.7
2 46 16.7 15 15.8
3 24 8.7 11 11.6
4 22 7.9 5 5.2
Clinical and psychological
Drug/alcohol abuse No 210 76.1 75 78.9 0.57
Yes 66 23.9 20 21.1
HADS anxiety >7 No 78 28.3 31 32.6 0.42
Yes 198 71.7 64 67.4
HADS depression >7 No 64 23.2 27 28.4 0.30
Yes 212 76.8 68 71.6
ET distress >4 No 147 53.3 54 56.8 0.54
Yes 129 46.7 41 43.2
ET need help >4 No 143 51.8 61 64.2 0.03
Yes 133 48.2 34 35.8
Note: aSocioeconomic groups (1, managers and liberal professionals; 2, clerical and services workers; 3, craft and machines workers; 4, unskilled laborers).
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In the original PMI study by Cleeland et al, 60% of 
patients with moderate to severe CRP were not prescribed 
an analgesic medication that was appropriate to their level of 
pain.13 Comparatively, our study had two important method-
ological differences. First, we used the BPI “average pain” 
rating as opposed to the “worst pain” rating used by Cleeland 
et al. We could have therefore underestimated the prevalence 
of PMI(−). Second, we categorized moderate and severe pain 
as numerical ratings in the 4–6 and 7–10 range, respectively, 
whereas the corresponding ranges in the Cleeland et al study 
were 4–7 and 8–10. This difference suggests that we could 
have comparatively overestimated the prevalence of PMI(−). 
The degree to which these two differences (acting in oppos-
ing directions) impacted our final estimate is unknown. The 
numerical cut points used for the severity categorization of 
pain have been keenly debated.30,31 A study based on CRP 
interference determined categorical ranges of 1–4 for mild, 
5–6 for moderate, and 7–10 for severe pain.32 A study based 
on the impact of pain on quality of life measures suggested 
that pain scores should be classified as 1–5 for mild, 6 for 
moderate, and 7–10 for severe pain.33 There is therefore 
some inconsistency in the published literature regarding the 
categorization of pain intensity and in the overall evaluation 
of CRP management.14,34 In previous palliative care studies, 
Table 3 Cancer and pain characteristics variables and their associations with PMI status (n=371)
Characteristics PMI positive PMI negative p-value
n % n %
Cancer
Primary cancer Head and neck 70 25.4 22 23.2 0.95
Lung 7 2.5 3 3.2
Gastrointestinal 61 22.1 21 22.1
Breast 31 11.2 12 12.6
Genitourinary 61 22.1 18 18.9
Other 46 16.7 19 20.0
Bone metastases No 182 65.9 60 63.2 0.62
Yes 94 34.1 35 36.8
Head/neck metastases No 254 92.0 93 97.9 0.04
Yes 22 8.0 2 2.1
Central nervous system metastases No 258 93.5 92 96.8 0.22
Yes 18 6.5 3 3.2
Chemotherapya No 150 54.3 54 56.8 0.67
Yes 126 45.7 41 43.2
Surgerya No 189 68.5 70 73.7 0.34
Yes 87 31.5 25 26.3
Radiotherapya No 134 48.6 61 64.2 0.008
Yes 142 51.4 34 35.8
Palliative goal No 140 50.7 55 57.9 0.23
Yes 136 49.3 40 42.1
Pain
Nociceptive visceral No 195 70.7 64 67.4 0.55
Yes 81 29.3 31 32.6
Nociceptive bone pain No 165 59.8 57 60.0 0.97
Yes 111 40.2 38 40.0
DN4 positive No 151 54.7 59 62.1 0.21
Yes 125 45.3 36 37.9
Breakthrough pain No 157 56.9 55 57.9 0.86
Yes 119 43.1 40 42.1
Incident pain No 105 38.0 46 48.4 0.07
Yes 171 62.0 49 51.6
No opioids No 263 95.3 66 69.5 <0.001
Yes 13 4.7 29 30.5
Adjuvant use No 112 40.6 49 51.6 0.06
≥1 164 59.4 46 48.4
Pain duration ≤3 months 147 53.3 45 47.4 0.32
>3 months 129 46.7 50 52.6
Note: aWithin the last 30 days before the initial consultation at the pain clinic; DN4 – neuropathic pain diagnostic questionnaire (positive: total score≥4).
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Cancer-related pain management and predictors of undertreatment
Table 4 Continuous variables and their associations with PMI status (n=371)
Variables PMI Mean SD 95% CI p-value
Age Positive 62.46 14.08 60.79–64.13 0.45
Negative 61.18 15.08 58.12–64.24
BPI_worst pain Positive 7.09 2.46 6.80–7.39 <0.001
Negative 8.15 2.81 7.58–8.72
BPI_least pain Positive 2.64 1.61 2.45–2.83 <0.001
Negative 4.03 2.21 3.58–4.48
BPI_average pain Positive 4.54 1.53 4.36–4.72 <0.001
Negative 6.05 2.41 5.56–6.54
BPI_pain right now Positive 5.02 2.42 4.73–5.31 <0.001
Negative 6.41 2.90 5.82–7.00
BPI_pain relief Positive 49.57 26.65 46.41–52.72 <0.001
Negative 30.42 31.59 23.99–36.86
BPI_ general activitya Positive 5.17 2.59 4.87–5.48 0.008
Negative 5.99 2.54 5.47–6.51
BPI_mooda Positive 7.53 2.43 7.24–7.82 0.48
Negative 7.33 2.43 6.83–7.82
BPI_walkinga Positive 5.20 2.62 4.89–5.51 0.12
Negative 5.67 2.42 5.18–6.17
BPI_worka Positive 4.45 2.92 4.09–4.79 0.47
Negative 4.69 2.89 4.10–5.28
BPI_relationsa Positive 2.97 1.88 2.75–3.20 0.87
Negative 3.01 1.90 2.62–3.40
BPI_sleepa Positive 4.97 1.91 4.74–5.19 0.23
Negative 4.69 1.92 4.30–5.09
BPI_enjoyment lifea Positive 7.37 2.44 7.08–7.66 0.37
Negative 7.63 2.37 7.15–8.11
DN4 score Positive 3.88 2.49 3.59–4.17 0.14
Negative 3.44 2.54 2.93–3.96
Note: aPain interference with the given variable; DN4 – neuropathic pain diagnostic questionnaire (positive: total score≥4).
Abbreviations: BPI, Brief Pain Inventory; CI, confidence interval; DN4, “Douleur Neuropathique 4”; PMI, pain management index; SD, standard deviation.
Table 5 Bivariable and multivariable logistic regression results for predictors of negative PMI (n=371)
Predictors variables Bivariable analyses Multivariable modela,b
OR 95% CI p-value OR 95% CI p-value
Age 0.99 0.98–1.01 0.45 0.99 0.97–1.00 0.14
Female sex 1.59 0.99–2.57 0.05 1.70 0.99–2.92 0.05
Drug/alcohol abuse 0.58 0.07–5.00 0.62
Palliative care goal 0.75 0.47–1.20 0.23
Head/neck metastases 0.25 0.06–1.08 0.06 0.26 0.05–1.32 0.10
CNS metastases 0.47 0.13–1.62 0.23
Radiotherapy in last 30 days 0.53 0.32–0.85 0.009 0.45 0.26–0.79 0.006
DN4 positive 0.74 0.46–1.19 0.21 0.54 0.30–0.97 0.04
Incident pain 0.65 0.41–1.05 0.07
No opioids 8.89 4.38–18.04 <0.001
Adjuvants≥1 0.64 0.40–1.02 0.06 0.57 0.32–0.99 0.05
Pain duration>3 months 1.27 0.79–2.02 0.32
ET_need help>4 0.60 0.37–0.97 0.04 0.55 0.32–0.96 0.03
BPI_interference with walking 1.08 0.98–1.18 0.12 1.09 0.98–1.21 0.13
BPI_interference with general activity 1.14 1.03–1.25 0.009 1.14 1.02–1.27 0.02
BPI_pain relief 0.96 0.95–0.97 <0.001 0.97 0.96–0.98 <0.001
Intercept 1.28 0.20–8.09 0.79
Notes: aModel’s goodness of fit: Hosmer–Lemeshow chi-square=6.33 (p=0.61). bModel’s discrimination: area under ROC=0.782.
Abbreviations: BPI, Brief Pain Inventory; CI, confidence interval; CNS, central nervous system; DN4, “Douleur Neuropathique 4” (neuropathic pain diagnostic questionnaire); 
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stable pain was defined as a pain intensity score of ≤3 for 
three consecutive days and the categorization for mild, mod-
erate, and severe was 0–3, 4–6, and 7–10, respectively.35,36 
A similar categorization was used in the current study and 
“average pain” was chosen as it was more reflective of the 
overall analgesia achieved in the week preceding initial PC 
consultation than an isolated single “worst pain” rating. 
Despite the definitional challenges, valid comparisons 
can be made with some studies. Mitera et al used the PMI 
to retrospectively assess CRP management in an outpatient 
palliative radiotherapy clinic using categories of 1–4 (mild), 
5–6 (moderate), and 7–10 (severe) for numerical “pain 
now” ratings; they reported a PMI(−) prevalence of 25.8%, 
comparable with our estimate of 25.6%.32 A culturally more 
comparable cross-sectional survey of patients in a variety of 
Portuguese palliative care settings included 151/164 (92%) 
patients with a cancer diagnosis.37 The median oral MEDD 
was 84 mg, whereas our study had a value of 30 mg. The PMI 
status was reported for 136 of these patients and was negative 
in only 4%. This lower prevalence estimate for PMI(−) sug-
gests better CRP management, which probably reflects the 
involvement of a palliative care team in their care. Overall, 
cross-sectional studies are limited to a narrow window of 
time and do not capture the dynamic changes in regard to 
pain intensity and its treatment. 
From the perspective of potential CRP undertreatment, it 
is important to also evaluate our study results in the context 
of published longitudinal data and aggregate data. Fisch 
et al performed a prospective, longitudinal study of pain and 
analgesics prescribed in 2,026 medical oncology outpatients 
with pain.38 Pain intensity scores were categorized according 
to the original Cleeland et al method and used to compute PMI 
values; 33% of patients had PMI(−) at initial assessment and 
no significant change occurred in follow-up 4–5 weeks later. 
Our 25.6% PMI(−) rate compares favorably with aggregate 
estimates from systematic reviews.16,17 In an initial systematic 
review published in 2008,16 43.4% of patients had PMI(−), 
reflecting inadequate CRP treatment; in a 2014 update with 20 
new studies,17 there was ~25% decrease in this figure to 31.8%. 
Both of these studies used the original Cleeland et al criteria 
to categorize pain. The substantive degree of inadequate CRP 
management in our and other studies prompts us to question 
what factors underpin this from a broader perspective.
Study’s prediction model of inadequate 
cancer pain treatment 
In the bivariable logistic regression analysis, “no opioid” sta-
tus was strongly associated with PMI(−) status. However, this 
proved not to be an independent predictor in the multivariable 
model, suggesting that confounding was an issue that led to 
this variable being dropped. Of the 42/371 (11.3%) patients 
who were not prescribed an opioid, 29/95 (30.5%) were in the 
PMI(−) group and 13/276 (4.7%) were in the PMI(+) group. 
Exclusion of the no opioid category in the final multivari-
able model would suggest that the prescription of too weak 
an analgesic (incongruent with the pain intensity reported) 
was perhaps more consistently associated with undertreat-
ment. We would have expected that having a documented 
palliative goal of treatment might have generated a more 
pain focused approach and led to a negative association with 
undertreatment, but this was not the case. However, docu-
mentation of a palliative goal of treatment is probably prone 
to inconsistency. Although socioeconomic factors have been 
consistently associated with undertreatment,17 our study failed 
to demonstrate such an association. The seven independent 
predictors of undertreatment were in the sex, psychosocial, 
and pain or pain management domains.
Sex association
We previously reported no sex difference in ratings of pain 
intensity in this study sample.20 Although female sex was not 
strictly a statistically significant independent predictor of 
undertreatment in the current study, it clearly was borderline 
with p=0.05. The MEDD in females was lower and the mean 
sex difference of logarithmically transformed MEDD was 
also borderline in terms of statistical significance (p=0.053). 
This suggests that being female had an association with CRP 
undertreatment and that relative opioid under prescribing in 
females occurred. 
Literature data regarding the association of female sex 
with CRP undertreatment are conflicting: some studies using 
the PMI have demonstrated an association,13,34,39 whereas 
others have not.10,16 Although female sex is associated with 
higher risk of chronic noncancer pain, the picture is less clear 
in relation to CRP, in which complex clustering with other 
symptoms such as depression and fatigue may compound 
the interpretive challenges.40 Regardless of sex association 
with CRP risk, this does not necessarily explain the tendency 
toward inadequate treatment in females, for whom a negative 
prescriber bias may exist. 
Psychological variables 
Among the psychological variables, a greater patient per-
ceived need for help (based on ET scores >4) had a nega-
tive association with PMI(−) status. Although this finding 
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interpretation is that the smaller proportion of those with ET 
scores >4 in the PMI(−) or undertreated group compared to 
the PMI(+) group, 35.8% versus 48.2%, respectively, might 
reflect a degree of denial and possibly an associated failure to 
acknowledge a need for help in those with PMI(−) status. We 
previously reported no relationship between psychological 
screening scores and pain intensity in this study sample.20 
Apart from the ET score difference in the current study, we 
found no association between other measures of anxiety, 
depression, or distress in this analysis. 
Radiotherapy association
Recent treatment with radiotherapy had an independent 
negative association with PMI(−) status: having radiation 
treatment lessened the likelihood of undertreatment of CRP. 
Although patients with higher pain intensity are probably 
more likely to be considered for radiation treatment, we 
postulate that exposure to specialist physicians in radiation 
oncology may result in more appropriate use of opioids to 
manage pain. 
Neuropathic pain and adjuvant use
The presence of a NeuCP reduces the odds of being under-
treated. The use of adjuvant medications is associated with 
PMI(−) status. Their use for NeuCP, which is known to be 
less opioid sensitive,41 is consistent with published guide-
lines.6 For patients with NeuCP and severe pain, adding an 
adjuvant drug may be more appropriate rather than changing 
a prescribed opioid or increasing its dosage.3 
BPI findings
The BPI ratings for pain interference with general activities 
had a positive independent association with PMI(−) status. 
Clinically, it is perhaps easier to interpret this BPI rating as 
an outcome rather than a statistical predictor. Similarly, the 
same could be said for the BPI rating of pain relief: the more 
a patient is undertreated for pain, the lower will be their rat-
ing for pain relief. 
Strengths and limitations of the study
Although our consecutive study sample consisted of 71% 
with metastatic disease, it included those who had CRP in 
association with recent surgery, chemotherapy, and radio-
therapy; consequently, it was relatively heterogeneous and 
representative of the spectrum of patients with cancer pain. 
The proportion with ECOG status in the 0–2 range was 
83.3%, which would be higher than most palliative care 
settings and thus more representative of the cancer disease 
population than many palliative care-based studies. 
There are some significant study limitations. First, the 
cross-sectional design limits assessment to a narrow tempo-
ral window of patients’ pain intensity experience. Second, 
referral bias is very likely with a PC, as reflected by 290 
patients (78.2%) having moderate or severe pain, and we 
cannot exclude the possibility of the same set of physicians 
referring undertreated patients with CRP. Also, the propor-
tion of study patients with lung cancer (2.7%) and head and 
neck cancer (24.8%) diagnoses are disproportionately low 
and high, respectively. Third, most patients had metastatic 
disease which arguably confines the generalization of the 
study findings to the more advanced cancer stages. Fourth, 
the PMI has several limitations as a tool, especially in rela-
tion to its fixed temporal assessment. It does not capture 
the dynamic changes in relation to pain intensity and the 
reactive speed and willingness of the prescriber to changing 
the dose of the analgesic in accordance with expressed pain 
level. It does not validly capture the impact of the multiple 
nonpharmacological and pharmacological (other than opioid 
prescribing) therapeutic interventions for pain management; 
it does not capture the complex multidimensional nature of 
CRP. Fifth, prescriber characteristics and attitudes were not 
examined. Similarly, we did not assess how patient’s attitudes 
and knowledge influenced their willingness to seek care, nor 
did we assess individual preferences or compliance with the 
prescribed analgesic regimen. Furthermore, we did not assess 
the impact of analgesic tolerance or drug tolerability on the 
adequacy of CRP treatment. 
Study implications 
Despite some limitations, the study findings have important 
implications for clinical practice, education, health policy, 
and research. We are concerned that because this study 
was conducted in one of the leading cancer institutions in 
 Portugal, these findings could reflect the “tip of the iceberg” 
at a national level. Further studies, including surveys, are 
needed to determine the true extent of the problem and its 
underpinnings. Nevertheless, given the study results, it is 
important to complete routine pain assessments in cancer 
patients to ensure that they receive appropriate analgesics 
and dosages are adjusted in a timely manner for effective 
CRP management. A broader approach is therefore needed in 
CRP management, including better education to ensure pain 
guidelines implementation; early palliative care referral for 
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practice standards.3,42 For instance, a case-based pain manage-
ment approach and a palliative care curriculum are effective 
in improving the opioid prescribing practices of medical 
residents.43 There are few studies that have investigated the 
characteristics/profile of physicians who have difficulty 
in controlling CRP. Such information would be useful in 
detecting those physicians who specifically need educational 
training to increase their CRP management skills.44 
It is likely that a better integration between oncologic 
and palliative/supportive care, as advocated by the European 
Society of Medical Oncology, may produce better outcomes 
for patients and families.45 Palliative care specialists may 
positively influence the cultural barriers – existing among 
physicians working at oncology centers – about the use of 
opioids. The brand new “National Plan on Palliative Care” 
billed in December 2016 in Portugal is a promising turning 
point for those suffering from advanced life-limiting diseases. 
Conclusion
Using the PMI(−) status to reflect undertreatment of cancer 
pain, approximately one in four patients suffering from CRP 
received inadequate analgesic treatment at the point of referral 
to a PC. We identified seven variables that were independently 
associated with undertreatment: female sex and patient ratings 
of greater interference with general activity were positively 
associated; radiation treatment, presence of neuropathic pain, 
use of one or more adjuvant analgesics, desire for emotional 
help, and perceived pain relief with current managements had 
negative associations with undertreatment. 
Future prospective studies across other care settings are 
warranted to further examine inadequate analgesic use in 
CRP management and the various predictors identified in 
association with this. Both patient and prescriber surveys are 
needed to determine barriers and enablers for optimal CRP 
management in the Portuguese context. 
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